JP2013048638A5 - - Google Patents

Download PDF

Info

Publication number
JP2013048638A5
JP2013048638A5 JP2012266674A JP2012266674A JP2013048638A5 JP 2013048638 A5 JP2013048638 A5 JP 2013048638A5 JP 2012266674 A JP2012266674 A JP 2012266674A JP 2012266674 A JP2012266674 A JP 2012266674A JP 2013048638 A5 JP2013048638 A5 JP 2013048638A5
Authority
JP
Japan
Prior art keywords
region
nogor
variant
cysteine
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012266674A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013048638A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013048638A publication Critical patent/JP2013048638A/ja
Publication of JP2013048638A5 publication Critical patent/JP2013048638A5/ja
Pending legal-status Critical Current

Links

JP2012266674A 2006-01-27 2012-12-05 Nogoレセプターアンタゴニスト Pending JP2013048638A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US76248706P 2006-01-27 2006-01-27
US60/762,487 2006-01-27
US83165906P 2006-07-19 2006-07-19
US60/831,659 2006-07-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008552443A Division JP5829373B2 (ja) 2006-01-27 2007-01-26 Nogoレセプターアンタゴニスト

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014168201A Division JP2014221076A (ja) 2006-01-27 2014-08-21 Nogoレセプターアンタゴニスト

Publications (2)

Publication Number Publication Date
JP2013048638A JP2013048638A (ja) 2013-03-14
JP2013048638A5 true JP2013048638A5 (enExample) 2013-05-30

Family

ID=38327911

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2008552443A Expired - Fee Related JP5829373B2 (ja) 2006-01-27 2007-01-26 Nogoレセプターアンタゴニスト
JP2012266674A Pending JP2013048638A (ja) 2006-01-27 2012-12-05 Nogoレセプターアンタゴニスト
JP2014168201A Withdrawn JP2014221076A (ja) 2006-01-27 2014-08-21 Nogoレセプターアンタゴニスト
JP2016040966A Withdrawn JP2016104821A (ja) 2006-01-27 2016-03-03 Nogoレセプターアンタゴニスト

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008552443A Expired - Fee Related JP5829373B2 (ja) 2006-01-27 2007-01-26 Nogoレセプターアンタゴニスト

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014168201A Withdrawn JP2014221076A (ja) 2006-01-27 2014-08-21 Nogoレセプターアンタゴニスト
JP2016040966A Withdrawn JP2016104821A (ja) 2006-01-27 2016-03-03 Nogoレセプターアンタゴニスト

Country Status (11)

Country Link
US (3) US8669345B2 (enExample)
EP (2) EP2526968A3 (enExample)
JP (4) JP5829373B2 (enExample)
CN (2) CN101420977B (enExample)
BR (1) BRPI0707276B1 (enExample)
CA (2) CA2913655A1 (enExample)
DK (1) DK1981902T3 (enExample)
ES (1) ES2550099T3 (enExample)
HR (1) HRP20151108T1 (enExample)
PT (1) PT1981902E (enExample)
WO (1) WO2007089601A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007089601A2 (en) * 2006-01-27 2007-08-09 Biogen Idec Ma Inc. Nogo receptor antagonists
US8992918B2 (en) 2008-03-13 2015-03-31 Yale University Reactivation of axon growth and recovery in chronic spinal cord injury
CA2818662C (en) * 2010-10-22 2021-07-06 Sungkyunkwan University Foundation For Corporate Collaboration Nucleic acid molecule inducing rna interference, and uses thereof
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP3514236A1 (en) 2012-05-22 2019-07-24 Olix Pharmaceuticals, Inc. Rna-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor
US10033029B2 (en) 2012-11-27 2018-07-24 Apple Inc. Battery with increased energy density and method of manufacturing the same
US9711770B2 (en) 2012-11-27 2017-07-18 Apple Inc. Laminar battery system
US10211433B2 (en) 2012-11-27 2019-02-19 Apple Inc. Battery packaging
US9899661B2 (en) 2013-03-13 2018-02-20 Apple Inc. Method to improve LiCoO2 morphology in thin film batteries
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US9601751B2 (en) 2013-03-15 2017-03-21 Apple Inc. Annealing method for thin film electrodes
US9887403B2 (en) 2013-03-15 2018-02-06 Apple Inc. Thin film encapsulation battery systems
US9570775B2 (en) 2013-03-15 2017-02-14 Apple Inc. Thin film transfer battery systems
US10141600B2 (en) 2013-03-15 2018-11-27 Apple Inc. Thin film pattern layer battery systems
US10930915B2 (en) 2014-09-02 2021-02-23 Apple Inc. Coupling tolerance accommodating contacts or leads for batteries
EP3377630A4 (en) 2015-11-16 2020-01-01 Olix Pharmaceuticals, Inc. Treatment of age-related macular degeneration using rna complexes that target myd88 or tlr3
WO2017134526A1 (en) 2016-02-02 2017-08-10 Olix Pharmaceuticals, Inc. Treatment of angiogenesis-associated diseases using rna complexes that target angpt2 and pdgfb
CN108779463B (zh) 2016-02-02 2022-05-24 奥利克斯医药有限公司 使用靶向IL4Rα、TRPA1或F2RL1的RNA复合物治疗特应性皮炎和哮喘
WO2017178883A2 (en) 2016-04-11 2017-10-19 Olix Pharmaceuticals, Inc. Treatment of idiopathic pulmonary fibrosis using rna complexes that target connective tissue growth factor
KR101916652B1 (ko) 2016-06-29 2018-11-08 올릭스 주식회사 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
US11591600B2 (en) 2017-02-10 2023-02-28 OliX Pharmaceuticals. Inc. Long double-stranded RNA for RNA interference
CN108359011B (zh) 2017-07-21 2019-06-25 华博生物医药技术(上海)有限公司 靶向于白介素17a的抗体、其制备方法和应用
CN107522783B (zh) * 2017-09-30 2020-07-07 华博生物医药技术(上海)有限公司 一种抗白介素17a的抗体、其制备方法和应用
CN111032095B (zh) * 2017-11-22 2022-07-01 弗门尼舍有限公司 鉴定能调节衣物恶臭、发霉恶臭和/或汗液恶臭的化合物的方法
CN114599676A (zh) 2019-10-24 2022-06-07 诺华康制药股份公司 新型抗-Nogo-A抗体
US12255308B2 (en) 2020-03-26 2025-03-18 Zeta Energy Llc Sulfurized-carbon cathode with conductive carbon framework
US11824220B2 (en) 2020-09-03 2023-11-21 Apple Inc. Electronic device having a vented battery barrier
WO2024117777A1 (ko) * 2022-11-29 2024-06-06 한국생명공학연구원 면역세포의 면역학적 간극 형성 촉진을 통해 세포용해 활성을 향상시키기 위한 NgR1 단백질의 활성 또는 발현 억제제

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3773319A (en) 1971-12-16 1973-11-20 Fabcor Ind Inc Corrugated sheet inverting machine
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
WO1983001451A1 (en) 1981-10-23 1983-04-28 Molecular Biosystems Inc Oligonucleotide therapeutic agent and methods of making same
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
AU631802B2 (en) 1988-06-14 1992-12-10 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1997891A1 (en) 1988-09-02 2008-12-03 Dyax Corporation Generation and selection of recombinant varied binding proteins
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
WO1991003162A1 (en) 1989-08-31 1991-03-21 City Of Hope Chimeric dna-rna catalytic sequences
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
WO1991014438A1 (en) 1990-03-20 1991-10-03 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5962219A (en) 1990-06-11 1999-10-05 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-selex
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
KR970002255B1 (ko) 1990-06-11 1997-02-26 넥스스타 파아마슈티컬드, 인크. 핵산 리간드
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69123979T2 (de) 1990-10-12 1997-04-30 Max Planck Gesellschaft Abgeänderte ribozyme
ATE218889T1 (de) 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ATE439435T1 (de) 1991-03-01 2009-08-15 Dyax Corp Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE4216134A1 (de) 1991-06-20 1992-12-24 Europ Lab Molekularbiolog Synthetische katalytische oligonukleotidstrukturen
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5756096A (en) 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化b−b10
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
EP0626012B1 (en) 1992-02-11 2003-07-09 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1994009817A1 (en) 1992-11-04 1994-05-11 City Of Hope Novel antibody construct
DE669986T1 (de) 1992-11-13 1996-10-10 Idec Pharma Corp Völlig unfunktionelle konsensus-kozak-sequenzen zur säugetier-exprimierung.
JPH08505872A (ja) 1993-01-22 1996-06-25 ユニバーシティ・リサーチ・コーポレイション 治療剤の局所化
US5624803A (en) 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
DK1231268T3 (da) 1994-01-31 2005-11-21 Univ Boston Polyklonale antistofbiblioteker
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JPH0856665A (ja) 1994-07-07 1996-03-05 Nederland Centr Org Toegepast Natuur Onder タンパク質分解酵素用の基質としての修飾された酵素前駆体
US5716824A (en) 1995-04-20 1998-02-10 Ribozyme Pharmaceuticals, Inc. 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
CA2207593A1 (en) 1994-12-13 1996-06-20 John Gustofson Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク. 免疫したゼノマウス(XenoMouse)に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6699843B2 (en) 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
US6068829A (en) 1995-09-11 2000-05-30 The Burnham Institute Method of identifying molecules that home to a selected organ in vivo
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
ATE373672T1 (de) 1996-01-16 2007-10-15 Sirna Therapeutics Inc Synthese von methoxynukleoside und enzymatische nukleisäure moleküle
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
WO1999066041A1 (en) 1998-06-16 1999-12-23 Human Genome Sciences, Inc. 94 human secreted proteins
CA2283740C (en) 1997-03-14 2006-06-27 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
US6011577A (en) 1997-06-30 2000-01-04 Polaroid Corporation Modular optical print head assembly
US6190370B1 (en) 1997-07-25 2001-02-20 Arrow International, Inc. Devices, systems and methods for determining proper placement of epidural catheters
KR100414936B1 (ko) 1997-09-12 2004-01-13 엑시콘 에이/에스 이환 및 삼환 뉴클레오시드, 뉴클레오타이드 및올리고뉴클레오타이드 동족체
CA2304982A1 (en) 1997-09-19 1999-03-25 Sequitur, Inc. Sense mrna therapy
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
US7041474B2 (en) 1998-12-30 2006-05-09 Millennium Pharmaceuticals, Inc. Nucleic acid encoding human tango 509
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
WO2000063364A2 (en) 1999-04-21 2000-10-26 American Home Products Corporation Methods and compositions for inhibiting the function of polynucleotide sequences
PT1178999E (pt) 1999-05-04 2007-06-26 Santaris Pharma As Análogos de l-ribo-lna
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
PL356887A1 (en) 2000-01-12 2004-07-12 Yale University Nogo receptor-mediated blockade of axonal growth
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
US7378248B2 (en) 2000-03-06 2008-05-27 Rigel Pharmaceuticals, Inc. In vivo production of cyclic peptides for inhibiting protein-protein interaction
AU2001245793A1 (en) 2000-03-16 2001-09-24 Cold Spring Harbor Laboratory Methods and compositions for rna interference
JP2003527856A (ja) 2000-03-17 2003-09-24 ベニテック オーストラリア リミテッド 遺伝子のサイレンシング
EP1309726B2 (en) 2000-03-30 2018-10-03 Whitehead Institute For Biomedical Research Rna sequence-specific mediators of rna interference
ATE513910T1 (de) 2000-05-30 2011-07-15 Johnson & Johnson Res Pty Ltd Methoden zur gensuppression mithilfe von rnai verstärkenden faktoren
DE60141409D1 (de) 2000-10-06 2010-04-08 Biogen Idec Inc Homologe des nogo rezeptors
AU2001297872B2 (en) 2000-11-17 2006-11-09 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
NZ545176A (en) 2001-01-29 2008-05-30 Biogen Idec Inc Modified antibodies reactive with CD20 and methods of use
JP2005507246A (ja) 2001-08-27 2005-03-17 ノバルティス アクチエンゲゼルシャフト Nogoレセプターホモログおよびそれらの使用
US7129085B2 (en) * 2001-10-11 2006-10-31 Bristol-Myers Squibb Company Polynucleotides encoding a human leucine-rich repeat domain containing protein, HLLRCR-1
JP2005519584A (ja) 2001-10-22 2005-07-07 ノバルティス アクチエンゲゼルシャフト Nogoレセプターホモログおよびそれらの使用
US7309485B2 (en) 2001-12-03 2007-12-18 Children's Medical Center Corporation Reducing myelin-mediated inhibition of axon regeneration
US20030113325A1 (en) 2001-12-03 2003-06-19 Zhigang He Reducing myelin-mediated inhibition of axon regeneration
EP1354892A1 (en) 2002-04-19 2003-10-22 Centre National De La Recherche Scientifique (Cnrs) Peptides capable of inducing attraction of the axonal growth and their use for treating neurodegenerative diseases
US7745151B2 (en) 2002-08-02 2010-06-29 Children's Medical Center Corporation Methods of determining binding between Nogo receptor and p75 neurotrophin receptor
MXPA05001615A (es) 2002-08-10 2005-08-19 Biogen Idec Inc Antagonistas del nogo receptor.
AU2004231742A1 (en) * 2003-04-16 2004-11-04 Biogen Idec Ma Inc. Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques
CA2535007A1 (en) 2003-08-07 2005-02-24 Biogen Idec Ma Inc. Nogo receptor antagonists
WO2005040379A2 (en) 2003-10-23 2005-05-06 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF RAS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2005059515A2 (en) * 2003-12-16 2005-06-30 Children's Medical Center Corporation Method for treating neurological disorders
WO2006124627A2 (en) * 2005-05-12 2006-11-23 Biogen Idec Ma Inc. Methods of treating conditions involving neuronal degeneration
WO2007025219A2 (en) 2005-08-25 2007-03-01 Biogen Idec Ma Inc. Nogo receptor polypeptides and polypeptide fragments and uses thereof
WO2007089601A2 (en) * 2006-01-27 2007-08-09 Biogen Idec Ma Inc. Nogo receptor antagonists

Similar Documents

Publication Publication Date Title
JP2013048638A5 (enExample)
JP2012095652A5 (enExample)
JP2009268467A5 (enExample)
JP2013539454A5 (enExample)
JP2011155981A5 (enExample)
EA201490039A1 (ru) Химерные и гибридные полипептиды фактора viii и способы их применения
JP2013523179A5 (enExample)
EA201692359A1 (ru) Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса
EA201400836A8 (ru) Получение дитерпена
JP2014501510A5 (enExample)
JP2016525888A5 (enExample)
JP2012115277A5 (enExample)
JP2011136997A5 (enExample)
JP2017534262A5 (enExample)
JP2012034696A5 (enExample)
JP2015154787A5 (enExample)
CA3169782C (en) Complete genome sequence of the methanogen methanobrevibacter ruminantium
BR112016020688A2 (pt) Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc)
CL2012002969A1 (es) Vector viral adenoasociado recombinante (raav) que comprende promotor de rodopsina quinasa humana especifica del fotorreceptor, o promotor de beta-actina de pollo cmv quimerico truncado ubicuo unido a al menos un adn que codifica una guanilato ciclasa; virion o particula viral infecciosa que comprende el vector; celula huesped; composicion que comprende el vector.
BR112013002729A2 (pt) inibidores de vírus de hepatite c
JP2010088434A5 (enExample)
RU2015119517A (ru) Новый способ лечения инфаркта миокарда с применением фрагмента hmgb1
MX2011012906A (es) Produccion recombinante de peptidos.
WO2011064664A3 (en) T cell receptors specific for immunodominant ctl epitopes of hcv
JP2014520527A5 (enExample)